Brynjelsen Sean's Form 4 filing
Eton Pharmaceuticals, Inc.ETON · filed Jun 5, 2025
- Accession no.
- 0001437749-25-019583
- Filed
- Jun 5, 2025
- Trade date
- Jun 3-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $3.59M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Brynjelsen SeanCIK 0001669976 | Director, Officer (President & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2025 | Common Stock | SSaleDisposed | −60,945 | $17.38F1,F6 | −$1,059,224.1 | 3,022,568 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −8,655 | $18.38F2,F6 | −$159,078.9 | 3,013,913 | Direct | |
| Jun 3, 2025 | Common Stock | SSaleDisposed | −400 | $19.02F3,F6 | −$7,608 | 3,013,513 | Direct | |
| Jun 4, 2025 | Common Stock | SSaleDisposed | −70,000 | $17.00F4,F6 | −$1,190,000 | 2,943,513 | Direct | |
| Jun 5, 2025 | Common Stock | SSaleDisposed | −70,000 | $16.81F5,F6 | −$1,176,700 | 2,873,513 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were sold in multiple trades at prices ranging from $17.00 to $17.88. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F2
The shares were sold in multiple trades at prices ranging from $18.15 to $18.85. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F3
The shares were sold in multiple trades at a price of $19.02.
Referenced by the price of 1 transaction in Table I.
- F4
The shares were sold in multiple trades at prices ranging from $16.86 to $17.20. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F5
The shares were sold in multiple trades at prices ranging from $16.62 to $17.15. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.
- F6
The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 5 transactions in Table I.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.